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Abstract
As interest in the gut microbiome has grown in recent years, attention has turned to the impact of 
our diet on our brain. The benefits of a high fiber diet in the colon have been well documented in 
epidemiological studies, but its potential impact on the brain has largely been understudied. Here, 
we will review evidence that butyrate, a short-chain fatty acid (SCFA) produced by bacterial 
fermentation of fiber in the colon, can improve brain health. Butyrate has been extensively studied 
as a histone deacetylase (HDAC) inhibitor but also functions as a ligand for a subset of G protein-
coupled receptors and as an energy metabolite. These diverse modes of action make it well suited 
for solving the wide array of imbalances frequently encountered in neurological disorders. In this 
review, we will integrate evidence from the disparate fields of gastroenterology and neuroscience 
to hypothesize that the metabolism of a high fiber diet in the gut can alter gene expression in the 
brain to prevent neurodegeneration and promote regeneration.
Keywords
Gut-brain axis; Neuroepigenetics; Butyrate; High fiber diet; Gut microbiome
Introduction
The relationship between our gut microbiota and nervous system is a large part of the gut-
brain axis that has attracted increasing interest in recent years. It is estimated that 90% of the 
cells in the human body are of microbial origin, and the vast majority of these microbiota are 
comprised of 15,000–36,000 species of commensal and symbiotic bacteria that reside within 
the lumen of the gut [1,2]. A diverse microbial community is crucial for our health and 
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disease prevention based on microbiome studies (i.e., metagenomic sequence analyses) and 
perturbed energy homeostasis that has been observed in germ free mice [3]. Although it is 
not yet clear how gut microbiota positively and negatively affect brain function, multiple 
mechanisms are likely to be involved. Gut bacteria, have a prodigious metabolic capacity 
and some microbe-derived metabolites enter the circulation and can cross the blood-brain 
barrier. There is growing evidence that these microbes produce neurotransmitters, such as 
GABA and serotonin, modulate the immune system, alter epigenetic markers and produce 
bioactive food components and energy metabolites [2,4,5]. Thus, dietary manipulation to 
achieve a symbiosis that can improve the health of the microbiome and our brains is an 
attractive idea currently under investigation.
In this review, we will focus on the short chain fatty acid (SCFA), butyrate, which is most 
commonly produced by bacteria in the colon, and its role as a potential therapeutic for 
neurological diseases. Butyrate is an attractive therapeutic molecule because of its wide 
array of biological functions, such as its ability to serve as a histone deacetylase (HDAC) 
inhibitor, an energy metabolite to produce ATP and a G protein-coupled receptor (GPCR) 
activator. Pharmacologically, butyrate has had a profoundly beneficial effect on brain 
disorders ranging from neurodegenerative diseases to psychological disorders. In this review, 
we will discuss how butyrate is made and the pharmacological effects of butyrate in 
neurological disorders. Finally, we will summarize the current evidence that high fiber, 
butyrate-producing diets are capable of improving the health of our brains.
Sources of Butyrate
Butyrate is synthesized via the fermentation of otherwise non-digestible fiber by bacteria in 
the colon. Two acetyl CoA molecules are condensed into acetoacetyl CoA, which is 
converted through L(+)-beta-hydroxybutyryl CoA and crotonyl CoA intermediates to butyryl 
CoA. Butyryl CoA is then converted to butyrate either by butyrate kinase or butyryl CoA 
and acetate CoA transferase (as shown in Figure 1) [6,7].
Bacteria, such as those from the Clostridium, Eubacterium, and Butyrivibrio genera, are able 
produce butyrate in the gut lumen at mM levels [7,8]. In addition to producing butyrate as an 
endpoint, bacteria produce fermentation intermediates, including lactate, succinate or 
formate, which are used by the bacteria themselves to proliferate and survive [9,10]. 
Butyrate is also utilized by microbiota and serves as the primary energy source of 
colonocytes (as discussed below), making this a vital and mutually beneficial relationship. 
High fiber foods, summarized in Table 1, that enable these butyrate-producing bacteria to 
thrive include resistant starches (e.g. whole grain and legumes) and fructo-oligosaccharides 
(FOS) (e.g. bananas, onions, and asparagus). In fact, within two weeks of a high FOS diet, 
rats showed increase butyrate in the large intestine without changing the total number of 
anaerobic bacteria [11]. Similar results were seen in another study with diets containing FOS 
as well as resistant starches, but were not observed in the starch free wheat bran diet, which 
produces less butyrate [12]. This study, as well as many others, demonstrates that different 
sources of fiber yield different levels of butyrate so care must be used in selecting the 
appropriate fiber diets to increase butyrate levels.
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Aside from being produced by bacterial fermentation, butyrate can also be produced in much 
lower concentrations by mammalian cells through fatty acid oxidation and glucose 
metabolism [13,14] and can be found in plant oils and animal fats [4]. Butyric acid (the acid 
form of butyrate) is also present in the milk of ruminant animals, such as cows. Butter 
contains 3–4% butyric acid, in the form of tributyrin (butyryl triglyceride), making it the 
richest dietary source of butyrate [15]. Interestingly, the term butyrate originates from the 
Greek word for butter [16,17]. One molecule of tributyrin is metabolized into three butyrate 
molecules by intestinal enzymes. Tributyrin (1 g/kg) was able to elevate portal vein 
concentrations of butyrate to 2.4 mM after 1 hour in rats [18].
The Functions of Butyrate
Histone Deacetylase Inhibitor
Histone acetylation is a post-translational modification by an epigenetic protein, which are 
proteins that bind to chromatin and influence chromatin structure to change the propensity 
that a gene is transcribed or repressed. Acetylated histones cause the chromatin structure to 
loosen by weakening electrostatic attraction between the histone proteins and the DNA 
backbone. This process enables transcription factors and the basal transcriptional machinery 
to bind and increases transcription. Acetyl groups are added to highly conserved N-terminal 
L-lysine residues by histone acetyltransferases (HATs) and removed by histone deacetylases 
(HDACs). Reduced HAT activity, lower global histone acetylation and transcriptional 
dysfunction are characteristics of many neurodegenerative diseases [19]. Thus, HDAC 
inhibitors have become attractive therapeutic candidates due to their ability to increase 
histone acetylation and promote the expression of prosurvival, proregenerative and 
proplasticity genes.
Sodium butyrate (NaB), the sodium salt form of butyrate commonly used in 
pharmacological studies, is a well-known HDAC inhibitor that results in increased histone 
acetylation when applied to cells in culture in the high micromolar range [20,21]. Studies 
from our own lab demonstrated that NaB treatment could resist oxidative stress in vitro and 
in vivo [22–25]. These salutary effects were highly correlated with HDAC inhibition as a 
mechanism of protection. In multiple models of Huntington’s disease, we have shown that 
NaB and phenylbutyrate, a structurally similar analog, rescues histone acetylation, prevents 
neuronal cell death and extends the lifespan of mice [23,26].
Numerous subsequent studies have shown that NaB’s salutary effects span many 
neurological disease models and aspects of the pathophysiology of disease. For example, 
NaB can protect neurons from cell death in models of Parkinson’s disease [27–29] and in 
cisplatin-induced hearing loss [30], where NaB was able to reverse the disease-associated 
reduction in histone acetylation. Similarly, NaB was able to reduce the infarct size in models 
of ischemic stroke, limiting the damage to the brain and improving behavioral outcomes 
[24,31–33]. In vitro and in vivo (via intraperitoneal injection) data from our own laboratory 
also suggests that butyrate can induce resistance to oxidative stress and increase histone 
acetylation and enhance gene expression of a number of genes in the high micromolar range 
[24,34]. Altogether, these observations are consistent with the idea that NaB can modulate 
the expression of a large number of genes to affect numerous pathophysiological pathways. 
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The prospect of accomplishing this goal with a single, naturally occurring small molecule is 
exciting.
NaB has also demonstrated a profound effect on improving learning and memory, 
particularly in cases of disease-associated or toxicity-induced dementia. In mouse models of 
Alzheimer’s disease, histone acetylation is restored and expression of learning-associated 
genes is increased with NaB treatment [35,36]. While NaB had no effect on the contextual 
memory on wild-type mice, contextual memory in the transgenic mouse model showed 
significant improvements, even at late stages of Alzheimer’s disease. These improvements in 
learning and memory have also been demonstrated in models of memory impairment from a 
toxic overload of metals [37,38], traumatic brain injury [39] or neurological infections 
[40,41].
As HDAC inhibitors influence the transcription of numerous genes, it seems unlikely that a 
single gene is responsible for its neurotrophic effects. However, many studies have shown 
that at least some of these beneficial effects can be attributed NaB’s ability to increase 
acetylation around the promoters of neurotrophic factors, such as BDNF, GDNF and NGF 
and thus increasing their transcription [41–48]. Other studies have demonstrated the 
importance of immediate early genes, including c-Fos and Homer1a, which are activity 
dependent genes involved in plasticity [44,49–52]. Based on these data, NaB is capable of 
upregulating a suite of genes that promote survival, plasticity and regeneration.
It should also be noted that the effects of HDAC inhibitors are not specific to histone 
proteins alone. In fact, a growing list of over 1700 proteins can be acetylated on their lysine 
residues, and HDAC inhibitors block their deacetylation as well [53]. Thus, the effect of 
HDAC inhibitors on non-histone proteins should not be overlooked. Acetylation plays an 
important role that affects the enzymatic and metabolic activity of many proteins. For 
example, our group has shown the transcription factor Sp1 is acetylated and activated by 
oxidative stress, and butyrate, as well as other HDAC inhibitors, can enhance this protective 
adaptive response to promote cell survival [22,23,54].
Metabolism and Mitochondria
Butyrate plays two major roles in metabolism and mitochondrial activity. First, butyrate can 
serve as an energy substrate. In fact, colonocytes have adapted to use butyrate as their 
primary source of energy, which accounts for approximately 70% of ATP produced [55]. 
Given overwhelming use of butyrate as an energy substrate in the colon and the microbiome, 
much of the research to date has focused on its metabolic effects in the colonic epithelium. It 
was recently shown that germ free mice, which lack a microbiome, had a significantly 
reduced NADH/NAD+ ratio and reduced ATP levels in the colon compared to 
conventionally raised mice with a normal microbiome [56]. Butyrate was able to rescue the 
diminished mitochondrial respiration in the germ free mice, which demonstrates its 
importance in energy homeostasis. It was also found that cancerous colonocytes undergoing 
the Warburg effect, defined by their preferential use of glycolysis rather than mitochondrial 
respiration, allows butyrate to accumulate in the nucleus where it can act as an HDAC 
inhibitor [57]. However, in normal coloncytes the cells rapidly utilize butyrate for energy via 
mitochondrial β-oxidation. Interestingly, mitochondrial metabolism of butyrate does produce 
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more acetyl-CoA, which can be used by HATs to add acetyl groups to proteins so under 
either condition butyrate could in theory increase acetylation and affect gene transcription.
While the metabolic events in the colon may appear disconnected from that of the brain, it’s 
important to consider the immense energy demands of the brain and the energy 
dyshomeostasis that occurs in the brain in many neurological diseases. Perhaps the best cited 
example is the reduced glucose utilization in the Alzheimer’s brain, which occurs at the 
earliest stages of the disease and well before memory loss [58,59]. This reduction in glucose 
utilization has prompted a number of studies to identify therapeutic strategies to provide 
alternative sources of energy to fulfill the brain’s energy requirements. For example, the use 
of caprylic triglycerides as a medical food to enhance ketogenesis via increasing β-
hydroxybutyrate has been shown to improve cognitive scores in Apo-E4 negative 
Alzheimer’s disease patients after 45 days [60]. Longer time points were less successful, but 
it is likely that these treatments would need to begin before significant cognitive symptoms 
to achieve maximum effectiveness. Currently no studies have examined the metabolic effect 
of gut-derived butyrate on the brain. However, we hypothesize that if sufficient butyrate 
levels could be reached in the brain, butyrate could stand in as an energy substrate, as in the 
colon, and restore energy homeostasis, but the precise concentration to affect brain 
physiology via changes in the diet, gut microbiome or through pharmacological 
supplementation remain undefined.
Reduced brain glucose availability is believed to contribute to mitochondrial dysfunction in 
acute and chronic neurological diseases but could, in theory, be aided by the presence of 
butyrate’s direct and indirect effects on energy metabolism. In this context, butyrate can: 1) 
directly affect energy metabolism by acting as a substrate for beta-oxidation; 2) can 
upregulate genes involved in mitochondrial biogenesis (e.g. PGC1α) via its effects as a 
selective HDAC inhibitor; and 3) via its ability to affect the acetylation of a wide number of 
metabolic proteins. This last effect of butyrate and other HDAC inhibitors on metabolism 
was brought to light by the studies demonstrating that nearly every enzyme involved in 
glycolysis, gluconeogenesis, the TCA cycle, fatty acid metabolism and glycogen metabolism 
is acetylated [61]. The potent HDAC inhibitor, TSA, was able to significantly increase 
acetylation of these proteins. In the case of malate dehydrogenase, acetylation was increased 
by both glucose and TSA to lead to increased activity levels. To a large degree, these studies 
have been replicated with NaB by the lab of João Quevedo, which showed that NaB can 
restore Complex I–IV, as well as the TCA cycle activity, after being repressed by 
amphetamines and ouabain in animal models of mania [62–64]. These studies demonstrate 
that butyrate is also capable of increasing mitochondrial activity, which can help to rectify 
the disease-associated mitochondrial dysfunction in the brain.
G Protein-Coupled Receptor Activator
G protein-coupled receptors (GPCR) are the largest and most diverse family of 
transmembrane proteins. They are comprised of 7 transmembrane α-helices, which bind 
extracellular signals, such as light-sensitive compounds, hormones, growth factors and 
neurotransmitters, and activate signal transduction pathways inside of the cell, primarily the 
cAMP and phosphatidylinositol signaling pathways [65]. With the role in detecting 
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extracellular signals, GPCRs are critical for a number of physiological functions including 
regulation of immune system, autonomic nervous system regulation, sensory (taste and 
smell) function, and maintaining energy homeostasis. Dysfunction of GPCRs is associated 
with a number of diseases, which has made them the target for more than 40% of prescribed 
drugs [4].
In 2003, two previously orphan GPCRs, with no known ligands (GPR41 and GPR43), were 
identified as receptor targets for SCFA and aptly renamed free fatty acid receptors (FFAR) 3 
and 2, respectively. Although GPR41 and GPR43 are related showing 52% sequence 
similarity and identified as tandemly encoded genes in chromosome 19, they differ on their 
preference in chain length of the SCFA ligands. FFAR2 is more specific to the shorter 
aliphatic chains of acetate and propionate, while FFAR3 preferentially binds propionate, 
butyrate and valerate [66].
FFAR3 appears to play a significant role in balancing energy metabolism through intestinal 
gluconeogenesis (IGN) and the sympathetic nervous system [67]. FFAR3 is highly 
expressed in the sympathetic nervous system and knockout of FFAR3 in mice show reduced 
sympathetic ganglion activity. What is most intriguing is that while it has been demonstrated 
that SCFA (propionate) activate the ganglia activity via FFAR3, the ketone body, β-
hydroxybutyrate, which is produced under conditions of starvation or ketosis but structurally 
similar to butyrate, inhibits ganglia activity by functioning as an antagonist to FFAR3. 
Although both butyrate and propionate are agonists of FFAR3 in the nervous system, only 
propionate uptake in the IGN is dependent on FFAR3. This finding demonstrates a novel 
interaction between metabolic substrates and sympathetic nervous system activity [68].
Butyrate also signals through GPR109a, which is widely expressed in the in colonocytes and 
T cells, but has also been found in microglia [69–72]. The expression of GPR109a is 
reduced in human colon cancer cells, and the forced expression of GPR109a in these cancer 
cells induces apoptosis [69]. While it requires millimolar concentrations of butyrate to 
activate these receptors, the concentration of butyrate in the colon is more than sufficient to 
enhance activity the GPR109a. This has the potentially protect the healthy colon tissue 
through its anti-inflammatory signaling. Indeed, butyrate was shown to suppress colonic 
inflammation by inducing apoptosis in T cells residing in the colon [70]. Interestingly, 
knocking down GPR109a (or its transporter Slc5a8) in these cells increased the 
inflammatory response. More recently, it was shown that GPR109a is upregulated in the 
substantia nigra in Parkinson’s disease patients, where immunostaining for GPR109a was 
colocalized with microglia [71]. Treatment with β-hydroxybutyrate induced anti-
inflammatory effects in both in vitro and in vivo models of Parkinson’s disease through 
GPR109a activation and down regulating NF-κB activation [72]. The neurons were also 
protected from LPS-induced injury and improved behavioral outcomes in the animal models. 
In contrast to the study above, where β-hydroxybutyrate was shown to be an FFAR3 
antagonist, here β-hydroxybutyrate is acting as a GPR109a agonist. However, the effect of β-
hydroxybutyrate with respect to GPCRs appears to be under significant debate, as other 
groups have identified β-hydroxybutyrate as a FFAR3 agonist [73]. However, the 
Parkinson’s disease studies demonstrate that the activation of GPR109a leads to anti-
inflammatory effects in the brain and suggest that it is a good target for therapeutics in PD.
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High fiber diets and the brain
High fiber diets have numerous reported health benefits in reducing risk of type 2 diabetes, 
colon cancer, obesity, stroke and cardiovascular disease, making it a widely recommended 
healthy diet. Many of the reported effects have been associated with the microbiome and its 
ability to produce SCFA, like butyrate. Much of the butyrate produced in the colon is used as 
an energy source by the colonocytes, but some butyrate can also exit the colon through the 
portal vein, where the liver absorbs another large portion [74,75]. However, the distal colon 
is not connected to the portal vein, allowing for some systemic butyrate to be circulated. 
Indeed, there are many reports of high fiber diets increasing blood levels of circulating 
butyrate [75–77]. These later reports raise the possibility that increases in circulating 
butyrate could affect CNS function directly.
To date, only a handful of studies have probed the mechanistic basis surrounding the 
beneficial neurological effects of the high fiber diet and butyrate. A recent study 
demonstrated that germ free mice have increased blood brain barrier (BBB) permeability, 
when compared with specific pathogen free mice containing a healthy microbiota [78]. The 
increased permeability was associated with decreased levels of tight junction proteins, 
claudin 5 and occludin in the frontal cortex, hippocampus and striatum. Colonizing the germ 
free mice with the butyrate-producing bacteria, Clostridium tyrobutyricum, or an oral gavage 
(for 3 days) of NaB restored BBB permeability to the healthy levels of the pathogen free 
mice, while simultaneously increasing brain histone acetylation and expression of occludin 
and claudin 5. This study demonstrated the strong and important connection between the 
microbiota, butyrate and the brain. Another study found significant immune benefits in the 
brain of mice fed a diet high in fermentable (soluble) fiber and found that they recovered 
faster from endotoxin-induced sickness [79]. Not only did the diet successfully increase all 
SCFAs in the colon, but they also found significant benefits by attenuating 
neuroinflammation resulting from the diet. Mice fed the soluble fiber diet showed an 
increase in IL-1RA, a cytokine and inhibitor of the pro-inflammatory, IL-1β, in the brain 
after exposure to the endotoxin, lipopolysaccharide (LPS) and a decrease in IL-1β and TNF-
α. IL-4 is a cytokine shown to increase IL-1RA and as expected IL-4 mRNA was also 
increased in the brains of mice on the soluble fiber diet after LPS treatment. IL-4 expression 
is enhanced by increased histone acetylation. Thus, the authors hypothesized that the 
elevated butyrate from the dietary fiber fermentation may contribute to the immune 
response. In contrast to the soluble fiber diets, splenocytes from mice on the insoluble fiber 
diet did not increase IL-4 production when exposed to butyrate in vitro.
The microbiome and cognition
Several studies have examined the beneficial effects of a high fiber diet on memory and 
cognition. In these studies the diet and/or microbiome are manipulated to enhance brain 
function. For example, children on a high fiber diet demonstrate better cognitive control (e.g. 
multitasking, working memory and maintaining focus) than children who typically ate a 
lower fiber diet [80]. Other studies have examined the effects of probiotics that would 
increase butyrate-producing bacteria. These studies showed that the probiotics reduced 
anxiety in rats and lowered psychological stress in human subjects [81]. A similar study in 
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subjects with chronic fatigue syndrome showed reduced anxiety, a common symptom of the 
disease, with the use of probiotics [82]. Another study provided healthy subjects with a 
fermented milk product and used fMRI to asses changes in the brain [83]. However, no 
significant difference was observed in fecal microbiota samples in patients who received the 
fermented milk product.
Perhaps one of the most interesting brain-microbiome connections lies in autism, where an 
overwhelming 70% of autistic children suffer from gastrointestinal (GI) symptoms [84]. The 
degree of GI symptoms, most commonly diarrhea and bloating, is often positively correlated 
with the severity of autism. This correlation has launched numerous studies to determine 
whether the microbiome of autistic patients differ from those without autism. Indeed these 
studies have found evidence of decreased Bifidobacteria and Prevotella and higher levels of 
Lactobacillus, Sutterella and Firmicutes based on cultures from fecal samples, and these 
differences appear to be independent of diet [84–87]. Some studies have even reported an 
alleviation of autism symptoms in children with late-onset autism with the use of 
vancomycin, a poorly absorbed antibiotic; though the effects quickly diminished after 
treatment ended [88]. Since many of the bacteria altered in autistic patients are important in 
the fermentation process that produces SCFAs, like butyrate, additional studies measured the 
SCFA content in autistic children. However, there are conflicting data as to whether or not 
this change in microbiota result in an increase or decrease in SCFAs in fecal samples 
[84,89]. Regardless, more studies would be necessary to determine if a change in SCFAs in 
the fecal matter is the result of poor absorption based on the increased gut permeability seen 
in autistic patients or excessive fermentation.
Interestingly, it has been hypothesized that elevated SCFAs in the circulatory system due to 
increased gut permeability or abnormal microbiota, may actually be detrimental to children 
with autism. Recent studies have shown that intracerebroventricular and peripheral 
injections of propionic acid (one carbon shorter than butyrate) during development results in 
autistic like behavior, including repetitive dystonic behaviors and object preference [90–94]. 
These behavioral changes were also observed to a lesser extent with butyric acid and acetic 
acid. However, this phenomenon has led to a rodent model of autism using propionic acid to 
induce autistic symptoms [95,96]. In agreement with these studies is the increased risk of 
autism with prenatal exposure to valproate, an anti-seizure and mood-stabilizing drug that is 
a carboxylic acid HDAC inhibitor, like butyrate [97–100]. Given the large increase in autism 
diagnoses in recent years, there is a significant interest in understanding the etiology of the 
disease. While there are certainly many factors at play, propionic acid has come under some 
scrutiny. It has become an increasingly common food preservative due to its antimicrobial 
properties, which has increased our exposure to propionic acid [101]. In general, there is 
overwhelming evidence of the beneficial effects of butyrate and other SCFAs, but based on 
the autism literature some caution is warranted when considering prenatal exposure and the 
developing brain.
Conclusion
Butyrate is multi-functional molecule that has significant potential as a therapeutic for the 
brain, both in its pharmacologic and dietary form. Figure 2 summaries the various proposed 
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mechanisms in which butyrate may influence brain health in a number of different 
neurological disorders. Pharmacologically, butyrate is capable of targeting many pathways 
with multiple mechanisms of action that are disease specific. The dietary sources of butyrate 
through a high fiber diet or a diet rich in natural sources of butyrate is a highly appealing 
approach, as it presents a simple and relatively low risk method to potentially improve 
outcomes in patients with brain disorders. Though much more research is needed to 
understand the effectiveness of these dietary interventions, they remain promising 
interventions that, if validated, may be used in the future in conjunction with traditional 
pharmacological treatments. As the current literature suggests, we can no longer overlook 
the importance of the gut-brain axis and nutrition in disease pathogenesis and treatment.
Acknowledgments
This work was supported by the NINDS of the National Institutes of Health under award number F32NS090819 
and the Dr. Miriam and Sheldon G. Adelson Program in Neurorehabilitation and Neural Repair.
References
1. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic 
characterization of microbial community imbalances in human inflammatory bowel diseases. Proc 
Natl Acad Sci U S A. 2007; 104:13780–5. [PubMed: 17699621] 
2. Stilling RM, Dinan TG, Cryan JF. Microbial genes, brain & behaviour - epigenetic regulation of the 
gut-brain axis. Genes Brain Behav. 2014; 13:69–86. [PubMed: 24286462] 
3. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, et al. Postnatal microbial colonization 
programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004; 
558:263–275. [PubMed: 15133062] 
4. Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL. Short chain fatty acids and their 
receptors: new metabolic targets. Transl Res. 2013; 161:131–140. [PubMed: 23146568] 
5. Selkrig J, Wong P, Zhang X, Pettersson S. Metabolic tinkering by the gut microbiome: Implications 
for brain development and function. Gut Microbes. 2014; 5:369–380. [PubMed: 24685620] 
6. Gottschalk, G. Bacterial Metabolism. Springer-Verlag; New York: 1979. 
7. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in 
the human colon. FEMS Microbiol Lett. 2002; 217:133–139. [PubMed: 12480096] 
8. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic 
relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000; 
66:1654– 1661. [PubMed: 10742256] 
9. Cummings, JH.; Rombeau, JL.; Sakata, T. Physiological and Clinical Aspects of Short-Chain Fatty 
Acids. Cambridge University Press; 2004. 
10. Topping DL, Clifton PM. Short-Chain Fatty Acids and Human Colonic Function: Roles of 
Resistant Starch and Nonstarch Polysaccharides. Physiol Rev. 2001; 81:1031–1064. [PubMed: 
11427691] 
11. Le Blay G, Michel C, Blottiere HM, Cherbut C. Prolonged Intake of Fructo-Oligosaccharides 
Induces a Short-Term Elevation of Lactic Acid-Producing Bacteria and a Persistent Increase in 
Cecal Butyrate in Rats. J Nutr. 1999; 129:2231–2235. [PubMed: 10573555] 
12. Perrin P. Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of 
aberrant crypt foci in rats. Gut. 2001; 48:53–61. [PubMed: 11115823] 
13. Pouteau E, Nguyen P, Ballèvre O, Krempf M. Production rates and metabolism of short-chain fatty 
acids in the colon and whole body using stable isotopes. Proc Nutr Soc. 2003; 62:87–93. [PubMed: 
12740063] 
14. Wolever TMS, Josse RG, Leiter LA, Chiasson JL. Time of day and glucose tolerance status affect 
serum short-chain fatty concentrations in humans. Metabolism. 1997; 46:805–811. [PubMed: 
9225836] 
Bourassa et al. Page 9
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Newmark HL, Lupton JR, Young CW. Butyrate as a differentiating agent: pharmacokinetics, 
analogues and current status. Cancer Lett. 1994; 78:1–5. [PubMed: 8180951] 
16. Parodi PW. Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. J Dairy 
Sci. 1999; 82:1339–1349. [PubMed: 10386321] 
17. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr 
Metab Care. 2012; 15:474–479. [PubMed: 22797568] 
18. Miyoshi M, Sakaki H, Usami M, Iizuka N, Shuno K, Aoyama M, et al. Oral administration of 
tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-
induced liver injury in rats. Clin Nutr. 2011; 30:252–258. [PubMed: 21051124] 
19. Sleiman SF, Basso M, Mahishi L, Kozikowski AP, Donohoe ME, Langley B, et al. Putting the 
“HAT” back on survival signalling: the promises and challenges of HDAC inhibition in the 
treatment of neurological conditions. Expert Opin Investig Drugs. 2009; 18:573–584.
20. Sealy L. The effect of sodium butyrate on histone modification. Cell. 1978; 14:115–121. [PubMed: 
667928] 
21. Candido E. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978; 14:105–
113. [PubMed: 667927] 
22. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, et al. Histone deacetylase 
inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an 
Sp1-dependent pathway. Proc Natl Acad Sci U S A. 2003; 100:4281–4286. [PubMed: 12640146] 
23. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone Deacetylase Inhibition 
by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington’s 
Disease Mice. J Neurosci. 2003; 23:9418–9427. [PubMed: 14561870] 
24. Langley B, D’Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, et al. Pulse inhibition of 
histone deacetylases induces complete resistance to oxidative death in cortical neurons without 
toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent 
neuroprotection. J Neurosci. 2008; 28:163–176. [PubMed: 18171934] 
25. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, et al. Transcriptional therapy with the 
histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune 
encephalomyelitis. J Neuroimmunol. 2005; 164:10–21. [PubMed: 15885809] 
26. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, et al. Neuroprotective effects 
of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem. 
2005; 280:556–563. [PubMed: 15494404] 
27. Sharma S, Taliyan R, Singh S. Beneficial effects of sodium butyrate in 6- OHDA induced 
neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behav 
Brain Res. 2015; 291:306–314. [PubMed: 26048426] 
28. Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone 
deacetylase inhibition. Brain Res. 2010; 1354:172–178. [PubMed: 20654591] 
29. St Laurent R, O’Brien LM, Ahmad ST. Sodium butyrate improves locomotor impairment and early 
mortality in a rotenone-induced Drosophila model of Parkinson’s disease. Neuroscience. 2013; 
246:382–390. [PubMed: 23623990] 
30. Drottar M, Liberman MC, Ratan RR, Roberson DW. The histone deacetylase inhibitor sodium 
butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope. 2006; 
116:292–6. [PubMed: 16467722] 
31. Kim HJ, Chuang DM. HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: 
potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am J Transl Res. 2014; 
6:206–223. [PubMed: 24936215] 
32. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier 
disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 
inhibition. J Cereb Blood Flow Metab. 2011; 31:52–57. [PubMed: 20978517] 
33. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit 
anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: 
multiple mechanisms of action. J Pharmacol Exp Ther. 2007; 321:892–901. [PubMed: 17371805] 
34. Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR. Histone Deacetylase 
Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between 
Bourassa et al. Page 10
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cancer and Neurodegeneration. Pharmaceuticals (Basel). 2011; 4:1183–1195. [PubMed: 
22582024] 
35. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves 
memory function in an Alzheimer’s disease mouse model when administered at an advanced stage 
of disease progression. J Alzheimers Dis. 2011; 26:187–197. [PubMed: 21593570] 
36. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 
histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. 
Neuropsychopharmacology. 2010; 35:870–880. [PubMed: 20010553] 
37. Sharma B, Sharma PM. Arsenic toxicity induced endothelial dysfunction and dementia: 
pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. 
Toxicol Appl Pharmacol. 2013; 273:180–188. [PubMed: 23921152] 
38. da Silva PF, Garcia VA, da Dornelles AS, da Silva VK, Maurmann N, Portal BCD, et al. Memory 
impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and 
ameliorated by sodium butyrate. Neuroscience. 2012; 200:42–49. [PubMed: 22067609] 
39. Dash PK, Orsi SA, Moore AN. Histone deactylase inhibition combined with behavioral therapy 
enhances learning and memory following traumatic brain injury. Neuroscience. 2009; 163:1–8. 
[PubMed: 19531374] 
40. Steckert AV, Comim CM, Igna DMD, Dominguini D, Mendonça BP, Ornell F, et al. Effects of 
sodium butyrate on aversive memory in rats submitted to sepsis. Neurosci Lett. 2015; 595:134–
138. [PubMed: 25888815] 
41. Barichello T, Generoso JS, Simões LR, Faller CJ, Ceretta RA, Petronilho F, et al. Sodium Butyrate 
Prevents Memory Impairment by Reestablishing BDNF and GDNF Expression in Experimental 
Pneumococcal Meningitis. Mol Neurobiol. 2015; 52:734–740. [PubMed: 25284351] 
42. Suzuki-Mizushima Y, Gohda E, Okamura T, Kanasaki K, Yamamoto I. Enhancement of NGF- and 
cholera toxin-induced neurite outgrowth by butyrate in PC12 cells. Brain Res. 2002; 951:209–217. 
[PubMed: 12270499] 
43. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, et al. Histone deacetylase inhibitors up-
regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J 
Neuropsychopharmacol. 2008; 11:1123–1134. [PubMed: 18611290] 
44. Mahan AL, Mou L, Shah N, Hu JH, Worley PF, Ressler KJ. Epigenetic modulation of Homer1a 
transcription regulation in amygdala and hippocampus with pavlovian fear conditioning. J 
Neurosci. 2012; 32:4651–4659. [PubMed: 22457511] 
45. Wei Y, Melas PA, Wegener G, Mathé AA, Lavebratt C. Antidepressant-like effect of sodium 
butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the Bdnf 
gene. Int J Neuropsychopharmacol. 2015; 18:1–10.
46. Varela RB, Valvassori SS, Lopes-Borges J, Mariot E, Dal-Pont GC, Amboni RT, et al. Sodium 
butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF 
and GDNF levels in brain of Wistar rats. J Psychiatr Res. 2015; 61:114–121. [PubMed: 25467060] 
47. Valvassori SS, Varela RB, Arent CO, Dal-Pont GC, Bobsin TS, Budni J, et al. Sodium butyrate 
functions as an antidepressant and improves cognition with enhanced neurotrophic expression in 
models of maternal deprivation and chronic mild stress. Curr Neurovasc Res. 2014; 11:359–366. 
[PubMed: 25233278] 
48. Intlekofer KA, Berchtold NC, Malvaez M, Carlos AJ, McQuown SC, Cunningham MJ, et al. 
Exercise and sodium butyrate transform a subthreshold learning event into long-term memory via 
a brain-derived neurotrophic factor-dependent mechanism. Neuropsychopharmacology. 2013; 
38:2027–2034. [PubMed: 23615664] 
49. Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DEH, Truong HT, et al. Chromatin 
remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron. 2005; 
48:303–314. [PubMed: 16242410] 
50. Pascual M, Do Couto BR, Alfonso-Loeches S, Aguilar MA, Rodriguez-Arias M, Guerri C. 
Changes in histone acetylation in the prefrontal cortex of ethanol-exposed adolescent rats are 
associated with ethanol-induced place conditioning. Neuropharmacology. 2012; 62:2309–2319. 
[PubMed: 22349397] 
Bourassa et al. Page 11
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
51. Ji M, Dong L, Jia M, Liu W, Zhang M, Ju L, et al. Epigenetic enhancement of brain-derived 
neurotrophic factor signaling pathway improves cognitive impairments induced by isoflurane 
exposure in aged rats. Mol Neurobiol. 2014; 50:937–944. [PubMed: 24553857] 
52. Zhong T, Qing QJ, Yang Y, Zou WY, Ye Z, Yan JQ, et al. Repression of contexual fear memory 
induced by isoflurane is accompanied by reduction in histone acetylation and rescued by sodium 
butyrate. Br J Anaesth. 2014; 113:634–643. [PubMed: 24838805] 
53. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation 
targets protein complexes and co-regulates major cellular functions. Science. 2009; 325:834–840. 
[PubMed: 19608861] 
54. Gensert JM, Baranova OV, Weinstein DE, Ratan RR. CD81, a cell cycle regulator, is a novel target 
for histone deacetylase inhibition in glioma cells. Neurobiol Dis. 2007; 26:671–680. [PubMed: 
17481908] 
55. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. 
Gut. 1980; 21:793–798. [PubMed: 7429343] 
56. Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, et al. The microbiome and 
butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011; 
13:517–526. [PubMed: 21531334] 
57. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates the 
mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012; 
48:612–626. [PubMed: 23063526] 
58. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral 
metabolic alterations in dementia of the Alzheimer type: positron emission tomography with 
[18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983; 7:590–598. [PubMed: 6602819] 
59. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical 
Alzheimer’s disease. Ann N Y Acad Sci. 2008; 1147:180–195. [PubMed: 19076441] 
60. Henderson S, Vogel J, Barr L. Study of the ketogenic agent AC-1202 in mild to moderate 
Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr 
Metab. 2009; 6:1–25.
61. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein 
lysine acetylation. Science. 2010; 327:1000–1004. [PubMed: 20167786] 
62. Valvassori SS, Calixto KV, Budni J, Resende WR, Varela RB, de Freitas KV, et al. Sodium butyrate 
reverses the inhibition of Krebs cycle enzymes induced by amphetamine in the rat brain. J Neural 
Transm. 2013; 120:1737–1742. [PubMed: 23851624] 
63. Moretti M, Valvassori SS, Varela RB, Ferreira CL, Rochi N, Benedet J, et al. Behavioral and 
neurochemical effects of sodium butyrate in an animal model of mania. Behav Pharmacol. 2011; 
22:766–772. [PubMed: 21989497] 
64. Lopes-Borges J, Valvassori SS, Varela RB, Tonin PT, Vieira JS, Gonçalves CL, et al. Histone 
deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic 
metabolic alterations induced by ouabain. Pharmacol Biochem Behav. 2015; 128:89–95. [PubMed: 
25433326] 
65. Vassart G, Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev 
Endocrinol. 2011; 7:362–372. [PubMed: 21301490] 
66. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G 
protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain 
carboxylic acids. J Biol Chem. 2003; 278:11312–11319. [PubMed: 12496283] 
67. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-chain fatty acids and 
ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). 
Proc Natl Acad Sci U S A. 2011; 108:8030–8035. [PubMed: 21518883] 
68. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. 
Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 
2014; 156:84–96. [PubMed: 24412651] 
69. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is 
a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a 
tumor suppressor in colon. Cancer Res. 2009; 69:2826–2832. [PubMed: 19276343] 
Bourassa et al. Page 12
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
70. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, et al. Butyrate 
suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated 
apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 2012; 302:G1405–G1415. [PubMed: 
22517765] 
71. Wakade C, Chong R, Bradley E, Thomas B, Morgan J. Upregulation of GPR109A in Parkinson’s 
disease. PLoS One. 2014; 9:e109818. [PubMed: 25329911] 
72. Fu SP, Wang JF, Xue WJ, Liu HM, Liu B, Zeng YL, et al. Anti-inflammatory effects of BHBA in 
both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent 
mechanisms. J Neuroinflammation. 2015; 12:1–14.
73. Won YJ, Lu VB, Puhl HL, Ikeda SR. β-Hydroxybutyrate modulates N-type calcium channels in rat 
sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. J Neurosci. 
2013; 33:19314–19325. [PubMed: 24305827] 
74. Tarini J, Wolever TMS. The fermentable fibre inulin increases postprandial serum short-chain fatty 
acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl Physiol Nutr Metab. 2010; 
35:9–16. [PubMed: 20130660] 
75. Wolever TMS, Chiasson JL. Acarbose raises serum butyrate in human subjects with impaired 
glucose tolerance. Br J Nutr. 2000; 84:57–61. [PubMed: 10961161] 
76. Priebe MG, Wang H, Weening D, Schepers M, Preston T, Vonk RJ. Factors related to colonic 
fermentation of nondigestible carbohydrates of a previous evening meal increase tissue glucose 
uptake and moderate glucose-associated inflammation. Am J Clin Nutr. 2010; 91:90–97. [PubMed: 
19889821] 
77. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing effects of 
dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin 
Nutr. 2005; 82:559–567. [PubMed: 16155268] 
78. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The gut microbiota 
influences blood-brain barrier permeability in mice. Sci Transl Med. 2014; 6:263ra158.
79. Sherry CL, Kim SS, Dilger RN, Bauer LL, Moon ML, Tapping RI, et al. Sickness behavior 
induced by endotoxin can be mitigated by the dietary soluble fiber, pectin, through up-regulation 
of IL-4 and Th2 polarization. Brain Behav Immun. 2010; 24:631–640. [PubMed: 20138982] 
80. Khan NA, Raine LB, Drollette ES, Scudder MR, Kramer AF, Hillman CH. Dietary fiber is 
positively associated with cognitive control among prepubertal children. J Nutr. 2015; 145:143–
149. [PubMed: 25527669] 
81. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of 
psychotropic-like properties of a probiotic formulation ( Lactobacillus helveticus R0052 and 
Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2010; 105:755–764. 
[PubMed: 20974015] 
82. Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, et al. A randomized, double-
blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue 
syndrome. Gut Pathog. 2009; 1:1–6. [PubMed: 19338677] 
83. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk 
product with probiotic modulates brain activity. Gastroenterology. 2013; 144:1394–1401. 
[PubMed: 23474283] 
84. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal 
status in children with autism--comparisons to typical children and correlation with autism 
severity. BMC Gastroenterol. 2011; 11:1–13. [PubMed: 21211058] 
85. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, et al. Reduced incidence of 
Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013; 
8:e68322. [PubMed: 23844187] 
86. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al. Pyrosequencing 
study of fecal microflora of autistic and control children. Anaerobe. 2010; 16:444–453. [PubMed: 
20603222] 
87. Williams BL, Hornig M, Parekh T, Lipkin WI. Application of novel PCR-based methods for 
detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy 
Bourassa et al. Page 13
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
samples from children with autism and gastrointestinal disturbances. MBio. 2012; 3:e00261–11. 
[PubMed: 22233678] 
88. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, et al. Short-Term 
Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism. J Child Neurol. 2000; 
15:429–435. [PubMed: 10921511] 
89. Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short 
chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis 
Sci. 2012; 57:2096–2102. [PubMed: 22535281] 
90. MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, et al. 
Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty 
acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 
2007; 176:149–169. [PubMed: 16950524] 
91. MacFabe DF, Cain NE, Boon F, Ossenkopp KP, Cain DP. Effects of the enteric bacterial metabolic 
product propionic acid on object-directed behavior, social behavior, cognition, and 
neuroinflammation in adolescent rats: Relevance to autism spectrum disorder. Behav Brain Res. 
2011; 217:47–54. [PubMed: 20937326] 
92. Thomas RH, Foley KA, Mepham JR, Tichenoff LJ, Possmayer F, MacFabe DF. Altered brain 
phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a 
potential model of autism spectrum disorders. J Neurochem. 2010; 113:515–529. [PubMed: 
20405543] 
93. El-Ansary AK, Ben Bacha A, Kotb M. Etiology of autistic features: the persisting neurotoxic 
effects of propionic acid. J Neuroinflammation. 2012; 9:1–14. [PubMed: 22212381] 
94. Brusque A, Mello C, Buchanan D, Terracciano S, Rocha M, Vargas C, et al. Effect of Chemically 
Induced Propionic Acidemia on Neurobehavioral Development of Rats. Pharmacol Biochem 
Behav. 1999; 64:529–534. [PubMed: 10548267] 
95. MacFabe DF, Rodriguez K, Hoffman JE, Franklin AE, Mohammad-A Y, Taylor AR, et al. A Novel 
Rodent Model of Autism: Intraventricular Infusions of Propionic Acid Increase Locomotor 
Activity and Induce Neuroinflammation and Oxidative Stress in Discrete Regions of Adult Rat 
Brain. Am J Biochem Biotechnol. 2008; 4:146–166.
96. Shultz SR, MacFabe DF, Martin S, Jackson J, Taylor R, Boon F, et al. Intracerebroventricular 
injections of the enteric bacterial metabolic product propionic acid impair cognition and 
sensorimotor ability in the Long-Evans rat: further development of a rodent model of autism. 
Behav Brain Res. 2009; 200:33–41. [PubMed: 19154758] 
97. Schneider T, Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: 
animal model of autism. Neuropsychopharmacology. 2005; 30:80–89. [PubMed: 15238991] 
98. Ingram JL, Peckham SM, Tisdale B, Rodier PM. Prenatal exposure of rats to valproic acid 
reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol. 2000; 22:319–
324. [PubMed: 10840175] 
99. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal 
valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 
309:1696–1703. [PubMed: 23613074] 
100. Cohen OS, Varlinskaya EI, Wilson CA, Glatt SJ, Mooney SM. Acute prenatal exposure to a 
moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J 
Dev Neurosci. 2013; 31:740–750. [PubMed: 24055786] 
101. Davidson, MP.; Sofos, JN.; Branen, AL. Antimicrobials in Food. 3. CRC Press; 2005. 
102. Smith JG, Yokoyama WH, German JB. Butyric acid from the diet: actions at the level of gene 
expression. Crit Rev Food Sci Nutr. 1998; 38:259–297. [PubMed: 9626487] 
Bourassa et al. Page 14
Neurosci Lett. Author manuscript; available in PMC 2017 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Interest in how diet influences brain function via the gut microbiome is growing
• Butyrate can protect the brain and enhance plasticity in neurological disease 
models
• Gut microbiota produce butyrate by fermenting carbohydrates in a high fiber 
diet
• Hypothesis: A high fiber diet can elevate butyrate to prevent/treat brain disorders
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Figure 1. 
Schematic representation of the carbohydrate fermentation pathways that lead to butyrate 
production in the large intestine. The final enzymes involved in the formation of butyrate 
are: a. Butyryl CoA:acetate CoA transferase b. Phosphotransbutyrylase/butyrate kinase. 
Adapted from Pryde et al. 2002 [7].
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Figure 2. 
The proposed mechanisms for the neuroprotective effects of butyrate and the diseases which 
may benefit from butyrate treatment or a high fiber diet.
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Table 1
Summary of the proportions of SCFA produced with different forms of carbohydrates. Adapted from Smith et 
al. 1998 [102].
Proportion of SCFA energy (kJ) produced
Carbohydrate Butyric Acid Propionic Acid Acetic Acid
Cellulose 0.33 0.24 0.43
Gum arabic 0.17 0.28 0.56
Lactulose 0.36 0.16 0.48
Oat bran 0.38 0.24 0.38
Pectic substances 0.32 0.17 0.51
Resistant starch 0.55 0.21 0.24
Wheatbran 0.34 0.23 0.42
Xylan 0.06 0.23 0.71
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